T123 LLC (d.b.a. i2020 Accelerator)
By rapidly de-risking novel science and enriching partner pipelines with best-in-class molecules, i2020 helps accelerate early stage drug discovery platforms towards advanced lead and clinical candidate level within a two-year time framework.
As a part of the Expert Systems integrated accelerator platform, i2020 has access to a vast scientific and global resource network tailored specifically to the needs of early drug development programs allows it to take on projects in a wide array of therapeutic areas, from immunology to infectious diseases and beyond. By successfully leveraging agile development principles and flexible partnering business models, i2020 plans to co-create 20-30 diverse drug discovery programs.
I2020 in the news
Dr. Ruben Abagyan presented at the event with a discussion on “Giga-Screening for Preclinical Candidates with a Defined Multi-Target Profile”, where he explored the challenges of rapid identification of first-in-class or best-in-class preclinical drug candidates, illustrating the topic with examples of Eilean Therapeutics’ program for “tough” targets such as FLT3 and BCL2.
i2020, an accelerator program backed by the San Diego-based venture company Torrey Pines Investment, has announced investments in Ogwen Therapeutics, Llydaw Therapeutics and Mwyngil Therapeutics.
i2020, an accelerator program backed by the San Diego-based venture company Torrey Pines Investment, has announced investments in a virology start-up Trawsfynydd Therapeutics, together with OrbiMed Advisors.
i2020 Accelerator Announces the Launch of Gwynant Therapeutics and Celyn Therapeutics to Develop Novel Small Molecules for Oncology Targets
i2020, an accelerator program backed by the San Diego-based venture company Torrey Pines Investment, has announced two new start-up investments together with OrbiMed Advisors. The start-up proceeds will finance new oncology-focused companies: Gwynant Therapeutics and Celyn Therapeutics.
i2020 Accelerator Announces New Investments in Cancer-, Inflammation- and Neurology-focused Therapeutics
i2020, an accelerator program backed by the San Diego-based venture company Torrey Pines Investment, has announced multiple start-up and follow-on investment rounds together with OrbiMed and a start-up investment in a European science-based venture, together with OrbiMed and BioGeneration Ventures (BGV).
i2020 Accelerator of Torrey Pines Investment in Breakthrough Cancer Programs together with OrbiMed
i2020, an accelerator program backed by the San Diego-based venture company Torrey Pines Investment, announces an up to $28.5M seed investment together with OrbiMed in four companies: Loch Lomond Therapeutics, Loch Eil Therapeutics, Loch Ness Therapeutics and Llyn Bala Therapeutics. Each of the four companies is engaged in innovative oncology discovery programs comprising breakthrough discovery-stage assets and drug targets.
Meet Torrey Pines Investment and i2020 Accelerator at the 38th Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 10, 2019 -- Meet Torrey Pines Investment and i2020 Accelerator at the 38th Annual J.P. Morgan Healthcare Conference, on January 13-16 2020 in San Francisco, California. The annual J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community.
